Ramino-Bio is developing an oral drug that enhances branched-chain amino acid (BCAA) catabolism, for treatment of metabolic diseases, with a rare genetic disorder as the first indication.
Chronically elevated BCAAs alter and disrupt metabolic pathways, leading to generation of toxic metabolites and pathologies. Ramino Bio’s novel oral compound reduces elevated circulating BCAAs by increasing their breakdown. The company aims to address the unmet need of a rare genetic metabolic disorder, MSUD. The company’s lead candidate can also be used to treat other metabolic indications characterized by elevated BCAA levels.
Maple syrup urine disease (MSUD), Insulin resistance, Type 2 diabetes, Heart failure with preserved ejection fraction
Prof. Yibin Wang, Inventor
Dorit Cohen-Carmon, PhD, CSO